Ticker Scorecard - RIGL Basics Company: Rigel Pharmaceuticals, Inc. IPO Date: December 7, 2000 Sector: Healthcare Industry: Biotech Market Cap: $353.89M Activated in VL: True Average Daily Range Avg Daily Range: $0.20 | 2.82% Avg Daily Range (30 D): $0.67 | 3.31% Avg Daily Range (90 D): $0.67 | 3.28% Institutional Daily Volume Avg Daily Volume: .11M Avg Daily Volume (30 D): .16M Avg Daily Volume (90 D): .18M Trade Size Avg Trade Size (Sh.): 24 Avg Trade Size (Sh.) (30 D): 53 Avg Trade Size (Sh.) (90 D): 56 Institutional Trades Total Inst.Trades: 1,597 Avg Inst. Trade: $1.35M Avg Inst. Trade (30 D): $3.84M Avg Inst. Trade (90 D): $2.54M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.5M Avg Closing Trade (30 D): $1.1M Avg Closing Trade (90 D): $2.6M Avg Closing Volume: 55.37K     News Dec 12, 2024 @ 12:30 PM Thérapeutique Knight annonce l’approbati... Source: N/A Nov 6, 2024 @ 9:59 AM T-Cell Lymphoma Pipeline Insight Analysis Report 2... Source: Researchandmarkets.Com May 10, 2024 @ 4:00 PM Rigel (RIGL) Upgraded to Buy: Here's What You Shou... Source: Zacks Equity Research May 7, 2024 @ 9:50 PM Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags... Source: Zacks Equity Research May 2, 2024 @ 2:01 PM ProPhase Labs, Inc. (PRPH) Expected to Beat Earnin... Source: Zacks Equity Research Financials   TTM Q3 2024 Q2 2024 Basic EPS $1.53 $.71 $-.06 Diluted EPS $1.52 $.7 $-.06 Revenue $ 157.47M $ 55.31M $ 36.84M Gross Profit $ 140.83M $ 47.28M $ 34.03M Net Income / Loss $ 3.88M $ 12.42M $ -1.03M Operating Income / Loss $ 9.5M $ 14.06M $ .45M Cost of Revenue $ 16.65M $ 8.03M $ 2.81M Net Cash Flow $ 6.28M $ 15.64M $ 10.48M PE Ratio 13.22     Splits Jun 27, 2024:   10:1 Jun 25, 2003:   9:1